The King’s College London Gene Therapy Vector Facility (GTVF) is a state-of-the-art facility established to support early-stage clinical trials with GMP-grade viral vector as drug substance or drug product. With a legacy dating back to 2006, the GTVF is one of the largest suppliers of GMP-grade viral vectors to European clinical trials, offering:
Over the last 10 years we have successfully manufactured over 120 batches, establishing ourselves as a trusted partner in the industry. Our expertise is tailored to support biotech companies and academic institutions including those shown here, providing the high-quality and end-to-end manufacturing solutions needed.
We understand the financial challenges of early-stage clinical trials, which is why our competitive pricing enables both grant funded and commercial groups to bring their therapies to the clinic without being hindered by commercial price tags.
Why work with the GTVF?
Clients choose to forge long-term partnerships with the KCL GTVF for a number of reasons:
Expertise
Large and highly skilled team set up to support clients with all elements of their GMP drug substance or drug product projects.
Value
Set up to provide competitively priced manufacturing solutions for first-in-human ATIMP trials for academic and commercial clients.
Legacy
Over 120 batches of high-quality retro- and lentiviral vectors manufactured for clients in the UK, Europe and USA in the last 10 years.
End-to-End
We manage all aspects of viral vector manufacture from sourcing plasmid, project management, production, QC release testing and regulatory support.
Get In Touch
Contact us to discuss your lentiviral vector, retroviral vector, and adeno-associated viral vector GMP manufacturing needs:
Partners
GTVF at KCL is part of the London Innovation Hub for Gene Therapies (London IHfGT). This initiative is designed to advance the clinical development of new genetic treatments through the production of GMP (Good Manufacturing Practise) viral vectors.
Set up in 2021 with £18m of funding from the independent research charity LifeArc, the Medical Research Council (MRC), and the Biotechnology and Biological Sciences Research Council (BBSRC), the hubs will operate as a coordinated network, sharing technical skills and resources.
